Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function
Status:
Completed
Trial end date:
2020-07-03
Target enrollment:
Participant gender:
Summary
Prospective, multicenter, randomized and open label study evaluating the benefit on renal
function at 12 months post-transplantation, with an immunosuppression without calcineurin
inhibitor at 3 months and combining mycophenolate sodium-Everolimus versus an
immunosuppression combining Everolimus-Tacrolimus, in de novo renal transplant patients.